Avicanna

Regulation is among the factors inhibiting the flow of capital to cannabis innovation. Institutions are afraid to invest, and “big pharma is not coming in as we would like to see happen.” That is according to Aras Azadian, who joined the Benzinga Cannabis Capital Conference in Miami...

Photo by Hakuna Matata on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Despite its growing popularity, the cannabis industry remains a risky business. Even as it becomes...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Until recently, innovation lay dormant in the quality-driven cannabis industry. However, an evolving regulatory environment, coupled with...